#Japan #Tokyo #Biomaterials #Abnous Podia

Abnous Podia Invest&Architect: Pioneering Biomaterials in Architecture

Abnous Podia Invest&Architect Inc. (APIA), based in Sumida, Tokyo, has officially commenced its operations focused on utilizing novel drug formulation technologies to develop biomaterials specifically designed for the architectural and infrastructure sectors. Announced on March 30, 2026, APIA aims to integrate advanced materials into everyday construction and living spaces, facilitating a sustainable future.

Background of APIA

The foundation of APIA addresses a significant demand within the construction and infrastructure domains for new materials that simultaneously meet environmental sustainability, resource recycling, durability, workability, and aesthetic requirements. The challenge lies in overcoming multiple barriers, such as performance validation, mass production, adherence to regulations, sales channels, and practical implementation at construction sites before groundbreaking innovations can penetrate the market broadly.

Leveraging expertise garnered in the pharmaceutical and medical device arenas, particularly in drug delivery systems (DDS), sustained release technologies, environmental responsiveness, and texture control, APIA brings a unique approach to material development in construction. This synergy reinforces their mission to innovate building materials that are not only high-performing but also practical for the industry.

Partnership with STUDIO 10X

APIA has partnered with the Tokyo Metropolitan Government's startup initiative, “TOKYO SUTEAM”, as part of the “Studio 10X” program, designed to support entrepreneurial ventures. This program provides aspiring entrepreneurs access to opportunities, challenges, and resources in various sectors including construction, logistics, environment, and urban development.

Through the STUDIO 10X program, APIA has refined its material development concepts, conducted hypothesis validation for business ideas, and explored potential partnerships to enhance their initiatives. Currently, APIA is advancing multiple projects involving biomaterials, wood modification, upcycling unused resources, natural adhesives, and microbial formulations.

Core Business Areas

APIA's operational focus encompasses three primary segments:

1. Advanced Biomaterials: Research and supply of high-performance biomaterials that take into consideration not just functionality but also mass production capabilities and global market potential. They aim to develop products backward from the sales strategy to ensure market readiness.

2. Material Licensing: They are engaged in intellectual property (IP) development and licensing of material technologies. This includes packaging production methods and processes to build licensing models and facilitate technology transfers to manufacturing and sales partners both domestically and abroad.

3. Project Development: This arm integrates material development and technology selection with the creation of commercially viable business plans, revenue-sharing models, and collaborative projects—streamlining the pathway from concept to market.

Ongoing Projects

APIA is currently engaged in developing a number of innovative materials and products, including:

• - Fire-Resistant and Waterproof Wood: Creating composite wood materials infused with functional substances to impart fire resistance, waterproofing, mold resistance, and other protective traits.
• - Biomaterial Wallpapers: Utilizing non-petrochemical, low-environmental impact materials derived from unused biomass and fermentation technologies for interior and exterior architectural applications.
• - Natural Adhesives: Upcycling unused resources like defatted milk powder to develop natural adhesives that possess waterproof and antimicrobial qualities.
• - Bio-Deodorants and Microbial Agents: Formulating materials and products aimed at solving various issues in both residential and industrial spaces through beneficial microorganisms and their byproducts.

Vision from the CEO

Ryuto Kawamata, Representative Director of Abnous Podia Invest&Architect, states, “Our goal at APIA is to seamlessly connect groundbreaking material technologies from laboratories to actual products used in architecture, infrastructure, and living spaces. Cutting-edge materials must not only be high-performing but also practical for mass production, compliant with regulations, and feasible in construction and sales. Through the support of STUDIO 10X, we have been able to transform material development from mere research into a tangible business approach.” He emphasizes a commitment to collaborate with partners across various domains to deliver innovative biomaterials from Japan to society at large.

Collaboration and Partnership Opportunities

APIA is looking to broaden its partnerships, especially in areas such as biodegradable materials from waste upcycling and organic/inorganic modification of concrete. They welcome inquiries regarding collaborative opportunities from companies facing challenges in utilizing unused resources or seeking alternative materials.

Company Overview

• - Company Name: Abnous Podia Invest&Architect Inc.
• - Location: 1-16-3 Yokokawa, Sumida, Tokyo
• - Established: March 30, 2026
• - Business Scope: Research and development of biomaterials, licensing of material technologies, project development in architecture and infrastructure, and supporting advanced building materials.
• - Website: https://www.abnous.co.jp/